Compare Citius Pharmaceuticals Inc (CTXR) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Lamb Weston Holdings Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Lamb Weston Holdings Inc trades at $47.87 (market cap $6.81B). The key difference: Lamb Weston Holdings Inc is far larger — about 500× Citius Pharmaceuticals Inc's market cap, and Lamb Weston Holdings Inc pays a 3.07% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Lamb Weston Holdings Inc for 66 Days on average.
| CTXR | LW | |
|---|---|---|
Market Cap | $13.62M | $6.81B |
Volume | 132,438 | 4,638,686 |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $66.57 |
52-Week Low | $0.48 | $38.48 |
Typical Hold Time | 17 Days | 66 Days |
Enterprise Value | $3.79M | $10.61B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% in the last session, with a bearish technical signal from moving averages but bullish oscillators. The company reported $7.1M revenue for the first nine months of fiscal 2026 from LYMPHIR sales, yet net losses persist, with a net income margin of -651.27%. Cash flow remains positive due to financing activities, and analyst consensus is strongly bullish with five buy ratings.
The outlook hinges on commercial execution of LYMPHIR, offering growth potential amid high losses. Key risks include sustained negative profitability, cash burn, and competitive pressures. Investors should weigh the speculative growth narrative against fundamental weaknesses.
Lamb Weston (LW) trades at $49.46, up 2.85% today, showing strong momentum with four consecutive earnings beats. The stock maintains a bullish technical signal with support at $49 and resistance at $50. Fundamentals show solid revenue growth from $4.1B in 2022 to $6.45B in 2025, though net margins compressed from 18.85% to 3.85%. Analyst consensus is mixed with 31.58% Buy ratings and a $53.71 price target, representing 8.6% upside potential.
LW offers potential through continued earnings outperformance and margin recovery initiatives, but faces risks from profit margin volatility and ongoing legal scrutiny. The stock's current valuation at 27x P/E appears reasonable given growth prospects, though investors should monitor execution on the Focus to Win cost-saving strategy and resolution of fiduciary investigation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
